Intrigued by GRHL2’s failure to strongly impact cell survival on its own, we wondered whether GRHL2 may sensitize GBM cells to apoptosis under conditions of enhanced transcriptional reprogramming, such as those induced by HDAC inhibitors [44,45,46]. The gene discussed is GRHL2; the disease is glioblastoma.